You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020113010
Dec 20202806
Jan 20212205
Feb 20212002
Mar 20213006
Apr 20213209
May 2021605
Jun 2021008
Jul 20210016
Aug 20210011
Sep 20210012
Oct 202116020
Nov 202112015
Dec 20211403
Jan 20222204
Feb 20221203
Mar 20222002
Apr 20224405
May 20223005
Jun 20223403
Jul 20221007
Aug 20222004
Sep 20222604
Oct 20222002
Nov 20221003
Dec 20221406
Jan 20235404
Feb 20233803
Mar 20231602
Apr 2023601
May 20231400
Jun 20232602
Jul 20232003
Aug 20231601
Sep 20231805
Oct 20233403
Nov 20233803
Dec 20231601
Jan 20241200
Feb 20241400
Mar 20242603
Apr 20241800
May 20242200
Jun 20242200
Jul 20242001
Aug 20241401
Sep 20242803
Oct 20241004
Nov 20242202
Dec 2024605
Jan 20251804
Feb 2025008
Mar 2025002
Apr 2025004
May 2025009
Jun 2025002
Total10830252